孕晚期注射HBIG阻断HBV母婴传播的病例对照研究  

The effect of injection Hepatitis B immunoglobulin in the third trimester to interrupt hepatitis B virus vertical transmis-sion: a case-control study

作　　者：尹玉竹[1] 周瑾[1] 张培珍[1] 

机构地区：[1]中山大学附属第三医院妇产科,广州510630

出　　处：《中国优生与遗传杂志》2013年第12期107-108,82,共3页Chinese Journal of Birth Health & Heredity

基　　金：广东省自然科学基金资助项目(05001670);广东省科技计划项目(2008B060600023)

摘　　要：目的探讨孕晚期注射乙肝免疫球蛋白(HBIG)对阻断HBV母婴传播有无作用。方法选取538例孕晚期注射HBIG和817例未注射HBIG的孕妇及其婴儿,比较两组的宫内感染率。结果 (1)HBIG组和对照组的宫内感染率分别为2.2%和1.1%,两组相比差异无统计学意义(P>0.05);(2)当母亲同为HBeAg阳性时,两组的宫内感染率相比,差异无统计学意义(4.14%vs.4.92%,P>0.05);当母亲同为HBV DNA阳性时,两组的宫内感染率相比,差异仍无统计学意义(3.14%vs.3.10%,P>0.05);(3)进一步将孕妇血清HBV DNA按浓度高低进行分层分析,当HBV DNA浓度相同时,两组的宫内感染率相比,差异无统计学意义(P>0.05)。结论孕期注射HBIG对阻断HBV母婴传播无明显作用,不推荐孕期使用HBIG。Objective： To evaluate the efficacy of injection hepatitis B immunoglobulin （HBIG） in the third trimester to interrupt HBV vertical transmission. Methods： There were 538 HBsAg positive pregnant women injected HBIG in the third trimester as cases, and 817 women did not inject HBIG as eontrals. The rate of intrauterine infection was compared between the two groups. Results： The rates of intrauterine infection in the HBIG group and control group were 2. 2% and 1.1% respectively, there was no significant difference between the two groups （ P 〉 0.05 ） ; The rates of intrauterine infection were no significant difference between the two groups when mothers were HBeAg positive or HBV DNA positive （4. 14% vs. 4. 92%, 3.14% vs. 3.10%, P 〉 0. 05）. When maternal serum HBV DNA concentration was in the same lever, the rates of intrauterine infection were still no significant difference between two groups （ P 〉 0. 05 ）. Conclusion ： There is no efficacy of HBIG injection in the third trimester to interrupt HBV vertical transmission.

关 键 词：乙型肝炎病毒 乙肝免疫球蛋白 母婴传播 宫内感染 

分 类 号：R714.251[医药卫生—妇产科学]